GlassScriptPhysician profile
Paul Yoshino
NPI 1063575223
$7,551.89
in general payments reported to CMS, 2019-2025
34 companies · $1,089 in 2025
The $1,089 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $936 · 2020: $330 · 2021: $1,004 · 2022: $1,120 · 2023: $1,247 · 2024: $1,825 · 2025: $1,089.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,160.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,637.83 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $697.16 | 2019-2025 | |
| Pfizer INC. | $585.28 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $532.95 | 2021-2025 | Verquvo, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $464.26 | 2021-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $454.60 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $413.76 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $314.30 | 2019-2025 | Brilinta, Farxiga |
| Lexicon Pharmaceuticals, INC. | $290.08 | 2023-2024 | Inpefa |
| Abbott Laboratories | $283.54 | 2023-2025 | Aveir |
| E.R. Squibb & Sons, L.L.C. | $274.57 | 2019-2023 | Camzyos |
| Scpharmaceuticals INC. | $177.85 | 2023-2025 | |
| Boston Scientific Corporation | $177.64 | 2019-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Edwards Lifesciences Corporation | $174.20 | 2023-2025 | Sapien 3 Ultra Resilia |
| Medtronic, INC. | $156.79 | 2022-2024 | Micra |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $128.41 | 2019 | |
| Kestra Medical Technology Services, INC. | $119.47 | 2022-2025 | Assure Wcd |
| Biotronik INC. | $95.74 | 2022-2024 | Biomonitor |
| Esperion Therapeutics, INC. | $85.71 | 2021-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $64.21 | 2025 | |
| Kiniksa Pharmaceuticals International, Plc | $46.60 | 2024 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $46.41 | 2023-2024 | Evkeeza |
| Novo Nordisk INC | $45.51 | 2024-2025 | Rybelsus, Ozempic |
| Heartflow, INC. | $40.18 | 2023-2025 | Ffrct |
| Philips North America LLC | $39.40 | 2019-2022 | |
| Medtronic Vascular, INC. | $33.40 | 2019-2020 | |
| Tactile Systems Technology INC | $29.70 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $29.16 | 2023 | Arcalyst |
| Abiomed | $23.27 | 2023 | Impella |
| Cvrx, INC. | $22.41 | 2024 | Barostim Neo System |
| Baxter Healthcare | $18.84 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Altathera Pharmaceuticals LLC | $17.47 | 2025 | Sotalol Hydrochloride |
| Ge Healthcare | $16.53 | 2019 | |
| Amarin Pharma, INC. | $14.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Yoshino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.